EACTS INNOVATION SUMMIT 2023
The European Association for Cardio-Thoracic Surgery (EACTS) is proud to host its inaugural Innovation Summit 2023, taking place in Paris from 21-22 April.
Led by Past Presidents, Friedhelm Beyersdorf and Mark Hazekamp, the Summit will bring together engineers, scientists and surgeons, as well as Industry leaders, politicians and EU MDR officials in a facilitated interactive working symposium to discuss new developments and the latest thinking on all forms of scientific progress that may help to improve the care for cardiothoracic surgical patients.
This ‘invitation-only’ two-day event will see world leaders from the surgical, research and associated academic specialities convene to explore, shape and plan the new future of cardiothoracic surgical interventions.
Topics will include a discussion of the latest Medical Device Regulations, ‘Treating the Untreatables’ and ‘Disruptive ideas and methods’. See further details in the programme outline below.
Programme Outline
08.30 Welcome, Purpose & Goals of the Summit F Beyersdorf, Freiburg
M Hazekamp, Leiden
08.45 Introduction B Keogh, Birmingham
SESSION 1: Improvement of current techniques
Chairmen: V Falk, Berlin; M Hazekamp, Leiden
09.15 Mini-HLM and new oxygenators J Arens, Twente
09.30 Mechanical heart valves without anticoagulation H Sievers, Lübeck
09.45 “Foldoplasty” mitral valve device P del Nido, Boston
10.00 Controlling AV function during DAVID-OP B Arabkhani, Leiden
10.15 Short term MCS: “Obstacles” from lab to clinical use B Meyns, Leuven
10.30 Shock waves for myocardial regeneration Gollmann-Tepeköylü, Innsbruck
10.45 Panel discussion Chairs, Presenters & J Holfeld, Innsbruck
11.15 Coffee Break
SESSION 2: Improve the early postoperative period
Chairmen: F Beyersdorf, Freiburg; T Krieg, Cambridge
11.45 Modern Redox Medicine H Sies, Düsseldorf
12.00 Preliminary clinical data J S Pooth, Freiburg
12.15 Parabiosis, young blood and young plasma transfusion, cross-circulation A Wagers, Boston
12.30 Preventing atrial fibrillation D Pijnappels, Leiden
12.45 Panel discussion Chairs, Presenters & T Seki, Karolinska
13.15 Lunch Break
SESSION 3: Organ perfusion and repair, multi-organ repair
Chairman: A Wagers, Boston
14.30 Isolated Organ Repair: ex-vivo perfusion M Siepe, Bern
14.45 Organ repair: Mitochondrial transplantation P del Nido, Boston
15.00 Organ repair: Centralized organ repair centres TBC – M. Rothblatt, Silver Spring
15.15 Multi-organ repair: controlled automated reperfusion of the whole body (CARL.) G Trummer, Freiburg
15.30 Panel discussion Chairs, Presenters & M Grimm, Innsbruck
16.00 Coffee Break
SESSION 4: Dissemination of cardiac surgery techniques to LMICs
Chairmen: P Perier, Bad Neustadt/Saale; R Sadaba, Pamplona
16.30 The unmet need of the many: cardiac surgery in LMIC’s P Zilla, Cape Town
16.45 CSIA: mission, accomplishments, future C Bolman, Minneapolis
17.00 Panel discussion Chairs & Presenters
SESSION 5: Medical Device Regulations (MDR)
Chairmen: B Meyns, Leuven; A Vincentelli, Lille
17.15 EU: New MDR – over-regulation or not? W Oosterlinck, Leuven
17.30 EACTS: New MDR – over-regulation or not?
P Myers, Geneva
17.45 AEPC: New MDR – over-regulation or not? S Qureshi, Bristol
18.00 Panel discussion Chairs & Presenters
18.15 Close
SESSION 6: Organ and Tissue Replacement
Chairmen: J Cremer, Kiel; M Engelse, Leiden
09.00 Xeno-Transplantation B Reichart, München
09.15 Bioprinting of small bypass grafts R Berndt, Kiel
09.30 3D-Bioprinting of organs TBC – M Rothblatt, Silver Spring
09.45 Apical mini-LVAD W Bothe, Freiburg
10.00 Future of TAH A Vincentelli, Lille
10.15 Panel discussion Chairs, Presenters & B Rylski, Freiburg
10.45 Coffee Break
SESSION 7: Treat the “Untreatable” Disease
Chairman: P del Nido, Boston
11.15 New insights in the pathogenesis of atherosclerosis A Haverich, Hannover
11.30 Cancer and Hypothermia T Seki, Karolinska
11.45 Longevity and Aging: cardiomyocyte cell cycle and aging S Siddiqi, Leiden
12.00 Induced pluripotent stem cells (iPSCells) TBC – S Yamanaka, Kyoto
12.15 Panel discussion Chairs & Presenters
12.45 Lunch Break
13.30 Keynote Lecture on Innovation
SESSION 8: Disruptive ideas and methods
Chairmen: M Czerny, Freiburg; R Milton, Leeds
14.00 In-vivo visualisation and molecular targeting of the cardiac conduction system W Goodyer, Stanford
14.15 Contractile heart tubes Biermann, Hamburg
14.30 Organoids on chips M Engelse, Leiden
14.45 Thoracic topic J Lodhia, Leeds
15.00 Panel discussion Chairs & Presenters
15.15 Summit outcomes, next steps, and actions F Beyersdorf, Freiburg
M Hazekamp, Leiden
15.30 Close
Programme and faculty subject to change
EACTS aims to sponsor a revolution in cardiothoracic surgery and the EACTS Innovation Summit 2023 will be the birth of that revolution.
Objectives
To provide a supportive environment for the exchange of ideas on the current state of cardiothoracic surgery and associated interventions
To pinpoint and explore both immediate and future healthcare challenges and shape the direction and detail of therapeutic interventions for tomorrow
To identify and explore promising start-up technologies and therapeutics in cardiothoracic care
To establish, support and return to a global network of innovative thought leaders, supporting further networking, bolstering cross-discipline cooperation and generating a buzz of innovation within the cardiothoracic field.
DATES
21-22 April 2023
OVERVIEW
This will be a facilitated, interactive, working symposium of surgeons, cardiologists, allied health professionals, engineers, industrialists, biochemists, scientists, health economists and other academics. We will set clear, tangible challenges for our professions, geared towards harnessing the latest thinking and most advanced technologies of tomorrow, to deliver life-saving, life-enhancing new treatments for our future patients.
WHERE
Set in the beautiful surroundings of Châteauform’ – Les prés d’Ecoublay (45 minutes from the centre of Paris), this will be a unique gathering of thought leaders from the world of cardiothoracic surgery and care, actively scanning the treatment horizons and setting the therapeutic agenda for the next 20 years.
